Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US9126973B2 · kind B2 · utility
0Cited by
6References
51Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2014 |
| Grant date | Sep 8, 2015 |
| Priority date | — |
| Expiry date | Sep 29, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.